Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genakumab Phase Ib/II in Acute Gout
NCT05328531Phase 2Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- May 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of genakumab in gout, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started May 2021; status: completed.
02
Drugs
genakumab
03
Conditions
gout
Beyond the preview
Go deeper on NCT05328531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05328531.